My title
» Cardiovascular

Cardiovascular

CARDIOVASCULAR CLINICAL TRIALS

 

STROKE/TIA
Study Link Study Status Study Title Principal Investigator
RESPECT-ESUS Active Randomized, double-blind, evaluation in secondary stroke prevention comparing the efficacy and safety of the oral thrombin inhibitor dabigatran etexilate (110 mg or 150 mg, oral b.i.d.) versus acetylsalicylic acid (100 mg oral

q.d.) in patients with embolic stroke of undetermined source (RESPECT ESUS)

PI: James Welker
VENOUS THROMBOEMBOLISM
Study Link Study Status Study Title Principal Investigator
MARINER Active Medically Ill Patient Assessment of Rivaroxaban Versus Placebo IN Reducing Post-Discharge Venous Thrombo-Embolism Risk PI: James Welker
CONGESTIVE HEART FAILURE
Study Link Study Status Study Title Principal Investigator
RELAX Active A multicenter, randomized, double-blind, placebo controlled phase IIIb study to evaluate the efficacy, safety

and tolerability of Serelaxin when added to standard therapy in acute heart failure patients

PI: Welker
CONNECT-HF Active Care Optimization Through Patient and Hospital Engagement Clinical Trial for Heart Failure (CONNECT-HF) PI: James Welker
EMPEROR-Reduced Active Empagliflozin Outcome Trial in Patients with Chronic Heart Failure with Reduced Ejection Fraction PI: James Welker
EMPEROR-Preserved Active Empagliflozin Outcome Trial in Patients with Chronic Heart Failure with Preserved Ejection Fraction PI: James Welker
PIONEER-HF Active Comparison of Sacubitril/Valsartan Versus Enalapril on Effect in NT-proBNP in Patients Stabilized from an Acute Heart Failure Episode PI: James Welker
 

HYPERLIPIDEMIA

Study Link Study Status Study Title Principal Investigator
ODYSSEY Active A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Effect of Alirocumab (SAR236553/REGN727) on the Occurrence of Cardiovascular Events in Patients Who Have Recently Experienced an Acute Coronary Syndrome PI: James Welker
MYOCARDIAL INFARCTION/ACUTE CORONARY SYNDROME
Study Link Study Status Study Title Principal Investigator
ARTEMIS Active Affordability and Real-world Antiplatelet Treatment Effectiveness After Myocardial Infarction Study PI: James Welker
Dal-GenE Active A phase III, double-blind, randomized placebo-controlled study to evaluate the effects of dalcetrapib on cardiovascular (CV) risk in a genetically defined population with a recent Acute Coronary Syndrome (ACS) PI: James Welker

 

Our Studies